Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy

Molecular Vision

Volumn 19, Issue , 2013, Pages 1125-1131

  Nishiguchi, Koji M ^a   Ushida, Hiroaki ^a   Tomida, Daisuke ^a   Kachi, Shu ^a   Kondo, Mineo ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN; VASCULOTROPIN;

AGE; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIRETINAL MEMBRANE; EYE; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA HOLE; SWINE; VITREOUS BODY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; AGING; AQUEOUS HUMOR; DIABETIC RETINOPATHY; HEPARITIN SULFATE; HUMANS; MIDDLE AGED; PROTEIN BINDING; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; YOUNG ADULT;

EID: 84878426785     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Klein R, Klein BE, Jensen SC, Moss SE. The relation of socio-economic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology 1994; 101:68-76. [PMID: 8302566].
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen H V, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic reti-nopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487. [PMID: 7526212].
3. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002; 133:70-77. [PMID: 11755 8 41].
4. Simó R, Hernandez C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51:1574-1580. [PMID: 1840 4258].
5. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinop-athy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243:3-8. [PMID: 15258777].
6. Fannon M, Forsten-Williams K, Dowd CJ, Freedman DA, Folkman J, Nugent MA. Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J 2003; 17:902-904. [PMID: 12626427].
7. Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS ONE 2010; 5:e13493.[PMID: 20975989].
8. Tomida D, Nishiguchi KM, Kataoka K, Yasuma TR, Iwata E, Uetani R, Kachi S, Terasaki H. Suppression of choroidal neovascularization and quantitative and qualitative inhibition of VEGF and CCL2 by heparin. Invest Ophthalmol Vis Sci 2011; 52:3193-3199. [PMID: 21296829].
9. Dreyfuss JL, Regatieri CV, Lima MA, Paredes-Gamero EJ, Brito AS, Chavante SF, Belfort R Jr, Farah ME, Nader HB. A heparin mimetic isolated from a marine shrimp suppresses neovascularization. J Thromb Haemost 2010; 8:1828-1837. [PMID: 20492474].
10. Lange C, Ehlken C, Martin G, Konzok K, Moscoso Del PJ, Hansen LL, Agostini HT. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res 2007; 85:323-327. [PMID: 17662276].
11. Bollineni JS, Alluru I, Reddi AS. Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Curr Eye Res 1997; 16:127-130. [PMID: 9068943].
12. Kjellén L, Bielefeld D, Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983; 32:337-342. [PMID: 6219905].
13. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105:1807-1818. [PMID: 10862796].
14. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence. Proc Natl Acad Sci USA 1983; 80:2272-2275. [PMID: 6572976].
15. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 1980; 86:688-693. [PMID: 6447156].
16. Parthasarathy N, Spiro RG. Effect of diabetes on the glycos-aminoglycan component of the human glomerular basement membrane. Diabetes 1982; 31:738-741. [PMID: 6219021].
17. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteo-glycan and laminin. Diabetes 1987; 36:374-381. [PMID: 2948855].
18. Raats CJ, Van Den BJ, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000; 57:385-400. [PMID: 10652015].
19. Yokoyama H, Hoyer PE, Hansen PM, Van Den BJ, Jensen T, Berden JH, Deckert T, Garbarsch C. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Diabetes 1997; 46:1875-1880. [PMID: 9356039].
20. van Det NF, Van Den BJ, Tamsma JT, Verhagen NA, Berden JH, Bruijn JA, Daha MR, van der Woude FJ. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int 1996; 49:1079-1089. [PMID: 8 6917 28].
21. Gharagozlian S, Borrebaek J, Henriksen T, Omsland TK, Shegarfi H, Kolset SO. Effect of hyperglycemic condition on proteoglycan secretion in cultured human endothelial cells. Eur J Nutr 2006; 45:369-375. [PMID: 16810465].
22. Vogl-Willis CA, Edwards IJ. High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 2004; 1672:36-45. [PMID: 15 05 6 491].
23. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527-532. [PMID: 6367725].
24. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15:1875-1891. [PMID: 14 6 4243].
25. Gandorfer A, Putz E, Welge-Lüssen U, Grüterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol 2001; 85:6-10. [PMID: 1113370 3].
26. Kjellén L, Lindahl U. Proteoglycans: structures and inter-actions. Annu Rev Biochem 1991; 60:443-475. [PMID: 18 8 3 2 01].
27. Nandini CD, Mikami T, Ohta M, Itoh N, Akiyama-Nambu F, Sugahara K. Structural and functional characterization of oversulfated chondroitin sulfate/dermatan sulfate hybrid chains from the notochord of hagfish. J Biol Chem 2004; 279:50799-50809. [PMID: 15385557].
28. Scott JE. The chemical morphology of the vitreous. Eye (Lond) 1992; 6:553-555. [PMID: 1289129].
29. Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H. Role of soluble vascular endothe-lial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 2008; 115:1916-1922. [PMID: 18718666].